Poor vaccine responsiveness towards third-dose mRNA vaccine of COVID-19 in Japanese older people

Hideharu Hagiya; Takao Hikita; Tomohiro Habu; Masaki Asada; Takashi Yorifuji; Shinichi Toyooka; Fumio Otsuka; Masanori Nakayama

doi:10.1016/j.jinf.2022.07.007

Poor vaccine responsiveness towards third-dose mRNA vaccine of COVID-19 in Japanese older people

J Infect. 2022 Oct;85(4):436-480. doi: 10.1016/j.jinf.2022.07.007. Epub 2022 Jul 11.

Authors

Hideharu Hagiya¹, Takao Hikita², Tomohiro Habu³, Masaki Asada⁴, Takashi Yorifuji⁵, Shinichi Toyooka³, Fumio Otsuka⁶, Masanori Nakayama⁷

Affiliations

¹ Department of General Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan. Electronic address: hagiya@okayama-u.ac.jp.
² Office of Innovative Medicine, Organization for Research Strategy and Development, Okayama University, Okayama, Japan; Laboratory for Cell Polarity and Organogenesis, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany.
³ Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
⁴ Departments of Medical Education, Kurashiki Central Hospital, Japan.
⁵ Department of Epidemiology, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Okayama, Japan.
⁶ Department of General Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.
⁷ Office of Innovative Medicine, Organization for Research Strategy and Development, Okayama University, Okayama, Japan; Laboratory for Cell Polarity and Organogenesis, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany. Electronic address: masanori.nakayama@okayama-u.ac.jp.

No abstract available

Keywords: Antibody; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Vaccine booster; Vaccine failure.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Viral
COVID-19* / prevention & control
Humans
Japan / epidemiology
Vaccines, Synthetic
mRNA Vaccines

Substances

Antibodies, Viral
Vaccines, Synthetic
mRNA Vaccines